Elderly residents who take metformin to treat type 2 diabetes mellitus (T2DM) have an increased risk of developing some form of dementia, according to a study published in the journal Progress in Neuro-Psychopharmacology and Biological Psychiatry. This is in addition to the higher risk already carried by those who have T2DM.
The study tracked more than 9,000 recruits for 12 years. Participants who took metformin showed a 2.2 percent higher incidence of developing all-cause dementia than the control group. The highest risk (2.3 percent) was for vascular dementia, followed by the Alzheimer’s type at 2.1 percent.
Although further study is needed to explore the connection between metformin and dementia risk in those with type 2 diabetes, “The effects of exposure duration and dosage on dementia and PD occurrence were also observed,” the study authors write. “Long-term metformin exposure in patients with T2DM may lead to the development of neurodegenerative diseases, including dementia and Parkinson’s disease.”
Get the latest information and other valuable topics at this two-day forum bringing together administrators, policy advocates, educators, researchers, gerontologists, and clinical professionals working to improve quality of care and lifestyle, operational efficiency, and resident safety and satisfaction for seniors and the professionals who care for them.